Treatment and Prevention of Postherpetic Neuralgia

Dworkin, Robert H.; Schmader, Kenneth E.
April 2003
Clinical Infectious Diseases;4/1/2003, Vol. 36 Issue 7, p877
Academic Journal
There have been 4 recent major advances in the treatment of postherpetic neuralgia (PHN) that are based on the results of randomized, controlled trials. These advances are the demonstrations that gabapentin, the lidocaine patch 5%, and opioid analgesics are efficacious in patients with PHN, and the report that nortriptyline and amitriptyline provide equivalent analgesic benefits for patients with PHN but that nortriptyline is better tolerated. The results of these clinical trials are briefly reviewed, and their implications for the treatment of patients with PHN are discussed. Despite these treatment advances, many patients remain refractory to current therapy, and the prevention of PHN has therefore become an important focus of current research. Research on administration of the varicella-zoster vaccine to prevent herpes zoster and on treatment of patients who have herpes zoster with combined antiviral and analgesic therapy to prevent PHN is discussed.


Related Articles

  • Insufficient evidence to recommend topical lidocaine as first-line treatment for postherpetic neuralgia. Zakrzewska, Joanna M // Evidence-Based Dentistry;Sep2007, Vol. 8 Issue 3, p85 

    Data sourcesThe Cochrane Pain, Palliative and Supportive Care Group Trials Register, Cochrane Central Register of Controlled Trials, Medline, Embase, LILACS (Latin American and Caribbean Health Sciences), SIGLE (System for Information on Grey Literature in Europe)(for conference proceedings) and...

  • NeurogesX presents positive data from trial of pain patch. Shrine, Jim // Medical Device Daily;6/11/2007, Vol. 11 Issue 111, p3 

    The article reports on the positive data being reported in Europe, where NeurogesX plans to seek its first approval, from a Phase III trial of the company's pain patch in treating postherpetic neuralgia. According to the 402-patient study, NGX-4010 has shown statistically significant pain relief...

  • Convergence Moves CNV1014802 into Phase 2 Trial.  // Drug Discovery & Development;May2012, Vol. 15 Issue 5, p26 

    The article reports on the phase 2 proof-of-concept study conducted by Cambridge, England-based Convergence Pharmaceuticals Ltd. for CNV1014802 which is a small-molecule, state-dependent sodium channel blocker for the treatment of pain associated with trigeminal neuralgia (TN).

  • Targeting Voltage-Gated Calcium Channels for Neuropathic Pain Management Perret, Danielle; Luo, Z. David // Neurotherapeutics;Oct2009, Vol. 6 Issue 4, p679 

    Summary: Voltage-gated calcium channels (VGCC) play obligatory roles in diverse physiological functions. Pathological conditions leading to changes in their biophysical properties and expression levels may cause malfunctions of VGCC-mediated activities, resulting in disease states. It is...

  • Evaluation of Symptom Heterogeneity in Neuropathic Pain Using Assessments of Sensory Functions Arning, Kathrin; Baron, Ralf // Neurotherapeutics;Oct2009, Vol. 6 Issue 4, p738 

    Summary: Classification of neuropathic pain has been based on disease entities, anatomical localization, or histological observations. Over the past decade, there has been an explosion in our understanding of the basic mechanisms of neuropathic pain. The exciting advances in basic science are...

  • EpiCept: promising pain cream offers risky route to lucrative market.  // PharmaWatch: Monthly Review;Mar2009, Vol. 8 Issue 3, p18 

    The article discusses the results of a Phase IIb trial in the U.S. that evaluated EpiCept Corp.'s NP-1 in post herpetic neuralgia. Results have shown that NP-1 has achieved its primary endpoint of superior pain relief. Despite such results, the company was expected to face problems over gaining...

  • The Placebo Response Relationship to Outcomes in Trials of Postherpetic Neuralgia. Irving, Gordon // Clinical Drug Investigation;2010, Vol. 30 Issue 11, p739 

    Placebo responses in controlled studies of neuropathic pain, including postherpetic neuralgia, have increased in recent years and may obscure benefits of potential treatments. Investigations of the basis of the placebo effect have revealed some of the anatomical and physiological substrates for...

  • R&D Update.  // PharmaWatch: CNS;May2008, Vol. 7 Issue 5, p11 

    The article offers news briefs related to research and development in the pharmaceutical industry in the U.S. Depomed Inc. initiates the Phase III clinical trial that aims to evaluate Gabapentin GR for curing postherpetic neuralgia. Anesiva Inc. will start a Phase III trial that evaluates Adlea,...

  • Depomed reports encouraging results from Phase III PHN trial.  // PharmaWatch: CNS;Jun2011, Vol. 10 Issue 6, p26 

    The article reports on the encouraging results of the Phase III postherpetic neuralgia (PHN) trial of Depomed Inc. It notes that the clinical trial conducted by the specialty pharmaceutical company has showed the efficacy of Gralise drug in treating PHN patients at least 65 years of age. It...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics